Latest revenue
$11.49B
as of 2026-03-31
Latest net income
$2.68B
as of 2026-03-31
Net margin
23.3%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $121.42B
- Enterprise value
- $156.31B
- P/E (trailing)
- 17.2×
- Forward P/E
- —
- P/B
- 6.05×
- Dividend yield
- 4.2%
- 52-wk high
- $62.89
- 52-wk low
- $42.52
- Beta
- —
- Shares out
- 2.04B
5-year trend
What this company does
Item 1.BUSINESS. General Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the…
AI summary unavailable — showing raw filing excerpt
Generated from BMY's filing dated 2026-02-11
Key risks
Item 1A.RISK FACTORS. Any of the risks and uncertainties described below could significantly and negatively affect our business operations, financial condition, operating results (including components of our financial results), cash flows, prospects, reputation or credit ratings now and in the future, which could cause the trading price of our common stock to decline significantly. Additional risks and uncertainties that are not presently known to us, or risks that we currently consider immaterial, could also impair our business operations, financial condition, operating results or cash flows. The following discussion of risk factors contains “forward-looking” statements, as discussed in…
AI summary unavailable — showing raw filing excerpt
Generated from BMY's filing dated 2026-02-11
Profitability
Net margin
14.6%
179.0%Return on equity
38.2%
169.7%Return on assets
7.8%
181.1%Leverage
Debt / equity
3.87×
17.0%Long-term debt / equity
2.32×
20.4%Debt / assets
79.5%
3.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $11.49B | +2.6% | $2.68B | +9.0% | 23.3% |
Q4 2025 2025-12-31 | $12.50B | +1.3% | $1.09B | +1409.7% | 8.7% |
Q3 2025 2025-09-30 | $12.22B | +2.8% | $2.20B | +81.8% | 18.0% |
Q2 2025 2025-06-30 | $12.27B | +0.6% | $1.31B | -22.0% | 10.7% |
Q1 2025 2025-03-31 | $11.20B | -5.6% | $2.46B | +120.6% | 21.9% |
Q4 2024 2024-12-31 | $12.34B | — | $72.0M | — | 0.6% |
Q3 2024 2024-09-30 | $11.89B | +8.4% | $1.21B | -37.2% | 10.2% |
Q2 2024 2024-06-30 | $12.20B | +8.7% | $1.68B | -19.0% | 13.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on BMY — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$4.5M
Net activity
−$4.5M
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-04-01 | David V Elkins EVP, Chief Financial Officer | Sale | 25,519 | $61.60 | $1.6M | |
| 2026-04-01 | David V Elkins EVP, Chief Financial Officer | Sale | 4,481 | $62.05 | $278.0K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns BMY
Institutional value
$27.92B
Total shares held
479.5M
Distinct holders
741
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 132.3M | $8.03B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 46.2M | $2.80B | — | New |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 25.0M | $1.52B | — | New |
| 4 | Bank of New York Mellon Corp | 23.3M | $1.41B | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 18.8M | $1.14B | — | New |
| 6 | Legal & General Group Plc | 16.9M | $1.02B | — | New |
| 7 | Invesco Ltd. | 15.5M | $940.7M | — | New |
| 8 | VANGUARD FIDUCIARY TRUST CO | 11.5M | $698.5M | — | New |
| 9 | DEUTSCHE BANK AG\ | 9.0M | $548.1M | — | New |
| 10 | UBS Group AG | 7.2M | $436.7M | — | New |
| 11 | Allianz Asset Management GmbH | 6.9M | $417.3M | — | New |
| 12 | Swiss National Bank | 6.0M | $362.3M | — | New |
| 13 | BNP PARIBAS FINANCIAL MARKETS | 5.9M | $360.7M | — | New |
| 14 | WELLS FARGO & COMPANY/MN | 5.9M | $360.7M | — | New |
| 15 | National Pension Service | 5.5M | $335.5M | — | New |
| 16 | California Public Employees Retirement System | 5.2M | $317.4M | — | New |
| 17 | Mitsubishi UFJ Asset Management Co., Ltd. | 5.1M | $308.8M | — | New |
| 18 | Vanguard Global Advisers, LLC | 4.7M | $287.2M | — | New |
| 19 | Russell Investments Group, Ltd. | 4.5M | $274.2M | — | New |
| 20 | LOS ANGELES CAPITAL MANAGEMENT LLC | 4.3M | $258.2M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BMY's latest filing finishes processing.